Method of Treating or Preventing Oxidative Stress-Related Diseases
Background:
The National Institute on Aging,
Laboratory of Neurosciences is seeking statements of capability or
interest from parties interested in collaborative research to
further develop, evaluate, or commercialize a uric acid analogue
for the treatment of neurodegenerative diseases, wound healing and
cardiovascular disease.
- Stroke is the third-leading cause of death and
the leading cause of severe neurological disability
worldwide.
- Americans will pay approximately $62.7 billion
dollars in 2007 for stroke-related medical costs and
disability.
Reactive oxygen species (ROS) and reactive
nitrogen species (RNS) produce oxidative stress to DNA, lipids and
proteins thus causing cellular and tissue damage. A number of
diseases are associated with oxidative stress including Alzheimer's
disease, ischemic stroke, heart disease, cancer, hepatitis, and
autoimmune disease. Uric acid is a natural antioxidant effective in
reducing ROS and research has shown that uric acid contributes
approximately two-thirds of all free radical scavenging capacity in
plasma.
Technology:
Because uric oxide is too
insoluble to be used as a therapeutic agent, scientists at the NIH
developed uric acid analogs with improved anti-oxidative and
solubility properties for use as free radical scavengers or
antioxidants. These analogs increased survival of PC12 and
hippocampal neurons after challenge by Fe, MPP and Glutamate. When
administered to a mouse model of focal ischemic stroke, these
compounds protect neuronal cells from ROS and reduce brain damage
and ameliorate neurological deficits. Other studies show a single
application of these analogs on skin lacerations in mice decreased
the time for wound repair. Available for licensing are methods of
treating ischemic stroke and wound healing, and for the prevention
or treatment of other oxidative stress-related diseases, such as
epilepsy, Parkinson's disease and dementia. Available for
licensing.
Value Proposition:
Novel uric acid analogs for use
as antioxidants to help reduce the risk of stroke, neurological
diseases and assisting with wound repair.
R&D Status:
Pre-clinical
IP Status: U.S.
Provisional Application filed Aug 2006
Contact
Information:
John D. Hewes, Ph.D.
NCI Technology Transfer Center
Phone: 301-435-3121
E-mail: Hewesj@mail.nih.gov
Reference: #555 VC